Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: Review of the clinical evidence and consensus statement on appropriate use in the USA

Nature Reviews Urology

Volumn 11, Issue 10, 2014, Pages 589-596

  Daneshmand, Siamak ^a   Schuckman, Anne K ^a   Bochner, Bernard H ^b   Cookson, Michael S ^c   Downs, Tracy M ^d   Gomella, Leonard G ^e   Grossman, H Barton ^f   Kamat, Ashish M ^f   Konety, Badrinath R ^g   Lee, Cheryl T ^h   Pohar, Kamal S ⁱ   Pruthi, Raj S ^j   Resnick, Matthew J ^k   Smith, Norm D ^l   Witjes, J Alfred ^m   Schoenberg, Mark P ⁿ   Steinberg, Gary D ^l  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; 5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT;

ARTICLE; BLUE LIGHT CYSTOSCOPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CYSTOSCOPY; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT RISK; PATIENT SAFETY; PRIORITY JOURNAL; UNITED STATES; URINE CYTOLOGY; ANALOGS AND DERIVATIVES; BLADDER; CARCINOMA, TRANSITIONAL CELL; CONSENSUS; DIAGNOSTIC USE; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AMINOLEVULINIC ACID; CARCINOMA, TRANSITIONAL CELL; CONSENSUS; CYSTOSCOPY; HUMANS; NEOPLASM INVASIVENESS; PHOTOSENSITIZING AGENTS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85027949194     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.245     Document Type: Article

References (46)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Bladder Cancer [online], http://seer.cancer.gov/statfacts/html/urinb.html (2014).
2. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-477 (2006).
3. Babjuk, M. et al. Guidelines on non muscle invasive bladder cancer (TaT1 and CIS). European Association of Urology [online], http://www.uroweb.org/gls/pdf/05-TaT1-Bladder-Cancer-LR.pdf (2013).
4. Hall, M. C. et al. Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314-2330 (2007).
5. James, A. C. & Gore, J. L. The costs of non-muscle invasive bladder cancer. Urol. Clin. North Am. 40, 261-269 (2013).
6. Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs (IARC Press, 2004).
7. Sfakianos, J. P., Kim, P. H., Hakimi, A. A. & Herr, H. W. The effect of restaging transurethral resection on recurrence and progression rates in patients with non-muscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J. Urol. 191, 341-345 (2014).
8. Fujikawa, A. et al. An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non muscle invasive bladder cancer. Indian J. Urol. 28, 267-270 (2012).
9. Aydin, M. et al. A prospective evaluation of second transurethral resection in non-muscle invasive bladder tumors. J. BUON 15, 514-517 (2010).
10. Schulze, M., Stotz, N. & Rassweiler, J. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach. J. Endourol. 21, 1533-1541 (2007).
11. Schwaibold, H. E., Sivalingam, S., May, F. & Hartung, R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97, 1199-1201 (2006).
12. Jahnson, S. et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand. J. Urol. Nephrol. 39, 206-210 (2005).
13. Zurkirchen, M. A., Sulser, T., Gaspert, A. & Hauri, D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: A must even for experienced urologists. Urol. Int. 72, 99-102 (2004).
14. Grimm, M. O. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J. Urol. 170, 433-437 (2003).
15. Brauers, A., Buettner, R. & Jakse, G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J. Urol. 165, 808-810 (2001).
16. Skolarus, T. A. et al. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology 78, 1345-1349 (2011).
17. Herr, H. W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 174, 2134-2137 (2005).
18. Burger, M. et al. ICUD-EAU international consultation on bladder cancer 2012: non muscle invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36-44 (2013).
19. Mark, J. R., Gelpi-Hammerschmidt, F., Trabulsi, E. J. & Gomella, L. G. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can. J. Urol. 19, 6227-6231 (2012).
20. Schmidbauer, J. et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol. 171, 135-138 (2004).
21. Jocham, D. et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J. Urol. 174, 862-866 (2005).
22. Grossman, H. B. et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 178, 62-67 (2007).
23. Fradet, Y. et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study. J. Urol. 178, 68-73 (2007).
24. Stenzl, A. et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer. J. Urol. 184, 1907-1913 (2010).
25. Hermann, G. G., Mogensen, K., Carlsson, S., Marcussen, N. & Dunn, S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: A randomized two-centre study. BJU Int. 108, E297-E303 (2011).
26. Grossman, H. B. et al. Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J. Urol. 188, 58-62 (2012).
27. Shen, P. et al. Effects of fluorescent light-guided transurethral resection on non muscle invasive bladder cancer: A systematic review and meta analysis. BJU Int. 110, E209-E215 (2012).
28. Yuan, H. et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: A meta-analysis of randomized controlled trials. PLoS ONE 8, e74142 (2013).
29. O'Brien, T. et al. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycinC in newly presenting non muscle invasive bladder cancer. BJU Int. 112, 1096-1104 (2013).
30. Burger, M. et al. Photodynamic diagnosis of non muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846-854 (2013).
31. HEXVIX® 85 MG. IPSEN [online], http://www.ipsen.co.uk/ipsen-product-hexvix.php (2013).
32. Package leaflet Hexvix®. PHOTOCURE [online], http://www.photocure.com/Specialty-areas/Bladder-cancer/Package leaflet Hexvix/(2011).
33. Kausch, I. et al. Photodynamic diagnosis in non muscle invasive bladder cancer: A systematic review and cumulative analysis of prospective studies. Eur. Urol. 57, 595-606 (2010).
34. Gravas, S., Efstathiou, K., Zachos, I., Melekos, M. D. & Tzortzis, V. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can. J. Urol. 19, 6269-6273 (2012).
35. Bunce, C. et al. The role of hexylaminolaevulinate in the diagnosis and follow-up of non muscle invasive bladder cancer. BJU Int. 105 (Suppl. 2), 2-7 (2010).
36. Witjes, J. A. et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.06.037.
37. Witjes, J. A. et al. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. Urology 84, 122-126 (2014).
38. Malmström, P. U. et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Scand. J. Urol. Nephrol. 46, 108-116 (2012).
39. Garfield, S. S., Gavaghan, M. B., Armstrong, S. O. & Jones, J. S. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can. J. Urol. 20, 6682-6689 (2013).
40. Malmström, P. U. et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: Analysis of health economic impact in Sweden. Scand. J. Urol. Nephrol. 43, 192-198 (2009).
41. Otto, W. et al. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin. Med. Oncol. 3, 53-58 (2009).
42. Dindyal, S., Nitkunan, T. & Bunce, C. J. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn. Ther. 5, 153-158 (2008).
43. Burger, M. et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur. Urol. 52, 142-147 (2007).
44. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003).
45. Frampton, J. E. & Plosker, G. L. Hexyl aminolevulinate in the detection of bladder cancer. Drugs 66, 571-578 (2006).
46. Bennison, C. et al. Benefit of hexaminolevulinate (HAL) technology for patients and healthcare systems in non-muscle invasive bladder cancer (NMIBC) in Italy. 10th HTAi Seoul (2013).